FDA Drug · D-0245-2026

Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark, Product of Denmark, Novo Nordisk A/S, Novo Nordisk Inc., Plainsboro, NJ 08536, NDC 0169-4501-14

Class II · Ongoing

Presence of Particulate Matter: Hair was found in a prefilled syringe

Affected lots / codes — check yours against thisLot #: RZFYK06, RZFYA53; Exp Date 3/31/2027

Recalling firm: Novo Nordisk Inc., Plainsboro, NJ
Classification: Class II (temporary or reversible harm possible)
Status: Ongoing
Quantity: N/A
Distribution: Nationwide within the United States.
Recall initiated: December 19, 2025
Classified: December 31, 2025
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0245-2026%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →